"10.1371_journal.pone.0112376","plos one","2014-11-11T00:00:00Z","Jimson W D’Souza; Smitha Reddy; Lisa E Goldsmith; Irina Shchaveleva; James D Marks; Samuel Litwin; Matthew K Robinson","Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, United States of America; Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, United States of America; Department of Anesthesia and Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America","Conceived and designed the experiments: JWD SR LEG SL MKR. Performed the experiments: JWD SR LEG IS. Analyzed the data: JWD SR LEG IS SL MKR. Contributed reagents/materials/analysis tools: JDM. Wrote the paper: JWD SR LEG SL MKR.","JDM is a member of the Merrimack Pharmaceuticals scientific advisory board. Merrimack Pharmaceuticals licensed the anti-ERBB3 scFvs described in this manuscript from UCSF. A patent does exist that covers the anti-ERBB3 antibodies described in this manuscript. That patent (US Patent #7,332,585 B2) lists James D. Marks as a co-inventor. As disclosed during the original submission, Dr. Marks, a co-author on this paper, is also on the advisory board of Merrimack Pharmaceuticals. Neither his position on the advisory board nor the fact US Patent #7,332,585 B2 was licensed to Merrimack Pharmaceuticals alters the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2014","11","Jimson W D’Souza","JWDS",7,TRUE,5,4,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
